VGX Signs Production Agreement to Support Cystic Fibrosis Trials
Posted on: Tuesday, 13 May 2008, 12:00 CDT
VGX Pharmaceuticals has signed a multi-year supply agreement to provide plasmid DNA to support the ongoing toxicology and clinical trials of the UK Cystic Fibrosis Gene Therapy Consortium, which is dedicated to the search for effective gene therapy for cystic fibrosis patients.
Under the terms of the agreement, VGX will provide multiple batches of a Cystic fibrosis transmembrane conductance regulator (CFTR) product to support clinical studies planned to run through 2010. If all options are exercised, several hundred grams of plasmid DNA will be provided, making this agreement one of the largest contracts for non-viral gene therapy products ever undertaken.
Deborah Gill, Consortium's lead investigator, said: "Our CpG-free product, utilizing technology developed by Cayla-InvivoGen, presented some unique challenges for large-scale production, but the Team at VGX used their vast expertise in producing non-viral products to meet our demanding timelines."
Source: Datamonitor
Related Articles
- VGX Pharmaceuticals Signs Multi-Year Production Agreement With the United Kingdom Cystic Fibrosis Gene Therapy Consortium
- Copernicus to Receive Increased Support From Cystic Fibrosis Foundation Therapeutics to Further Development of Its Non-Viral Gene Therapy for Cystic Fibrosis
- AGTC and JDRF Announce Partnership to Develop Gene Therapy for Diabetic Eye Disease
- Copernicus to Receive Continued Support From Cystic Fibrosis Foundation Therapeutics to Further Develop Non-Viral Gene Therapy for Cystic Fibrosis
- Avigen's Gene Therapy Technology Acquired By Genzyme
- PhereSys Therapeutics Announces Consulting Agreement With Advanced Cell & Gene Therapy, LLC
- Vectors; Enzyme protects cells during gene therapy
- University of Florida; Enzyme protects cells during gene therapy
- Primer on Medical Genomics Part X: Gene therapy
- Benefits of some gene therapy may not outweigh its dangers
 |
 |
User Comments (0)
RSS Feeds